In vivo dosimetry in cancer patients undergoing intraoperative radiation therapy.
| Autor: | Petoukhova A; Haaglanden Medical Centre , Department of Medical Physics, Leidschendam, The Netherlands., Snijder R; Haaglanden Medical Centre , Department of Medical Physics, Leidschendam, The Netherlands., Vissers T; Haaglanden Medical Centre , Medical Library, Leidschendam, The Netherlands., Ceha H; Haaglanden Medical Centre , Department of Radiation Oncology, Leidschendam, The Netherlands., Struikmans H; Haaglanden Medical Centre , Department of Radiation Oncology, Leidschendam, The Netherlands. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Physics in medicine and biology [Phys Med Biol] 2023 Sep 08; Vol. 68 (18). Date of Electronic Publication: 2023 Sep 08. |
| DOI: | 10.1088/1361-6560/acf2e4 |
| Abstrakt: | In vivo dosimetry (IVD) is an important tool in external beam radiotherapy (EBRT) to detect major errors by assessing differences between expected and delivered dose and to record the received dose by individual patients. Also, in intraoperative radiation therapy (IORT), IVD is highly relevant to register the delivered dose. This is especially relevant in low-risk breast cancer patients since a high dose of IORT is delivered in a single fraction. In contrast to EBRT, online treatment planning based on intraoperative imaging is only under development for IORT. Up to date, two commercial treatment planning systems proposed intraoperative ultrasound or in-room cone-beam CT for real-time IORT planning. This makes IVD even more important because of the possibility for real-time treatment adaptation. Here, we summarize recent developments and applications of IVD methods for IORT in clinical practice, highlighting important contributions and identifying specific challenges such as a treatment planning system for IORT. HDR brachytherapy as a delivery technique was not considered. We add IVD for ultrahigh dose rate (FLASH) radiotherapy that promises to improve the treatment efficacy, when compared to conventional radiotherapy by limiting the rate of toxicity while maintaining similar tumour control probabilities. To date, FLASH IORT is not yet in clinical use. (© 2023 Institute of Physics and Engineering in Medicine.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|